Evidence map›Paper›PMID 41963194›Full record

ArticleScience bulletin2026

Genome wide association analysis and association of genetic risk and lifestyle with upper gastrointestinal cancer among an endoscopy-screened cohort in China.

Feifan He, Xianhui Ran, Hao Jiang, Zhiyuan Fan, Yueying Zhang, Jinwu Wang, Changqing Hao, Guohui Song, Yanwei Gong, Yanyan Li and 7 more

Abstract read
In one paragraph

Article in Science bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Association ofFrontiers in cellular and infection microbiology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Feifan HeNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Xianhui RanHealth Checkup Center, China-Japan Friendship Hospital, Beijing 100029, China.
Hao JiangChinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Zhiyuan FanHealth Checkup Center, China-Japan Friendship Hospital, Beijing 100029, China.
Yueying ZhangNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Jinwu WangLinzhou Cancer Hospital, Linzhou 456550, China.
Changqing HaoLinzhou Cancer Hospital, Linzhou 456550, China.
Guohui SongDepartment of Epidemiology, Cancer Institute/Hospital of Ci County, Handan 056500, China.
Yanwei GongDepartment of Epidemiology, Cancer Institute/Hospital of Ci County, Handan 056500, China.
Yanyan LiCancer Center, Feicheng People's Hospital, Feicheng 271600, China.
Xinqing LiNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Ru ChenNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Haoyu ZhangDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20850, USA.
M Constanza CamargoDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20850, USA.
Christian C AbnetDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20850, USA.
Shaoming WangNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. Electronic address: wangshaoming@cicams.ac.cn.
Wenqiang WeiNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing 211166, China. Electronic address: weiwq@cicams.ac.cn.

Funding

Upper Gastrointestinal Cancer StudiesZIACP000185 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI ABNET, CHRISTIAN · 2009 to 2025
$25.6M
Intramural NIH HHS Z99 CA999999Intramural NIH HHS ZIA CP000185
6 · The paper itself

Abstract

Esophageal squamous cell carcinoma (ESCC) and gastric cancer (GC) are influenced by genetic and lifestyle factors. We quantified genetic, lifestyle, and joint effects on upper gastrointestinal (UGI) cancer and evaluated the clinical utility of polygenic risk scores (PRS) for risk stratification. We included 5556 participants from a prospective endoscopy-screened cohort in high-risk regions (Linzhou, Cixian, and Feicheng) of China. Parallel genome-wide association studies of ESCC and GC were conducted using baseline and follow-up cases. Cancer type-specific PRSs were applied using the developed models in Chinese populations. Information on smoking, alcohol use, body mass index, physical activity, and diet was collected to construct a healthy lifestyle score (HLS). Multivariable logistic and Cox models evaluated associations between PRS, HLS, and UGI cancer risk, and risk stratification was assessed by combining PRSs with non-genetic factors. 1050 ESCC and 1015 GC cases were identified, including 203 ESCC and 170 GC incident cases diagnosed during a median follow-up of 5.2 years. A potentially novel GC locus at 6p12.1 (rs72875397) was identified. Higher PRSs were associated with increased risk of ESCC (HR: 1.20; 95% CI: 1.05-1.37) and GC (HR: 1.44; 95% CI: 1.24-1.67). Individuals with high PRS and unfavorable lifestyle had 2.75-fold and 4.18-fold increased risk of ESCC and GC. Adding PRSs to non-genetic models yielded improvements in C-index for ESCC (6.5%) and GC (7.2%). Gradients of benefit from favorable lifestyle were observed across PRS strata, with substantial reductions in cumulative incidence among individuals at high genetic risk (ESCC: from 14.24% to 5.08%; GC: 13.23% to 4.85%). In summary, PRSs improved risk stratification, and favorable lifestyle reduced UGI cancer risk across genetic strata, especially in those with high PRS, supporting risk-informed personalized prevention.

Indexed as

Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaGastrointestinal NeoplasmsGenetic Predisposition to DiseaseGenome-Wide Association StudyLife StyleStomach NeoplasmsAgedChinaFemaleGenetic Risk ScoreHumansMaleMiddle AgedPolymorphism, Single NucleotideProspective StudiesEsophageal squamous cell carcinomaGastric cancerGenome-wide association studyHealthy lifestylePolygenic risk scoreUpper gastrointestinal cancer

Identifiers

PMID41963194
PMCPMC13180336

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.